Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.50 | 43.00 | -0.48% |
| CAC 40 | 8,479.87 | 28.20 | -0.33% |
| DAX 40 | 25,817.89 | 38.58 | 0.15% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,651.77 | 27.26 | -0.26% |
| HKSE | 23,517.70 | 98.62 | -0.42% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,540.78 | 1,196.91 | -1.72% |
| NZX 50 Index | 13,769.55 | 6.45 | 0.05% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,797.10 | 42.30 | -0.48% |
| SSE Composite Index | 3,999.03 | 42.21 | -1.04% |